tradingkey.logo
搜尋

Evotec SE

EVO
添加自選
2.700USD
-0.020-0.74%
收盤 05/15, 16:00美東報價延遲15分鐘
958.28M總市值
虧損本益比TTM

Evotec SE

2.700
-0.020-0.74%
查看詳細走勢圖
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.74%

5天

-12.05%

1月

-16.15%

6月

-10.60%

今年開始到現在

-12.34%

1年

-33.50%

TradingKey Evotec SE股票評分

單位: USD 更新時間: 2026-05-15

操作建議

Evotec SE當前公司基本面數據相對穩定,最新ESG揭露屬於行業領先水平。增長潛力較大。當前估值合理,在生物技術與醫療研究行業排名149/382位。機構持股佔比非常高,近一月多位分析師給出公司評級為持有。最高目標價為4.67。中期看,股價處於下降通道。近一個月,市場表現較差,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Evotec SE評分

相關信息

行業排名
149 / 382
全市場排名
281 / 4482
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Evotec SE亮點

亮點風險
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
利潤高增長
公司淨利潤處於行業前列,最新年度總收入888.92M美元
估值高估
公司最新PE估值-4.24,處於3年歷史高位
機構減倉
最新機構持股9.58M股,環比減少5.75%
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉,最新持倉0.00股

分析師目標

基於 3 分析師
持有
評級
4.667
目標均價
+71.57%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Evotec SE新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Evotec SE簡介

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
公司代碼EVO
公司Evotec SE
CEOWojczewski (Christian)
網址https://www.evotec.com/
KeyAI